Standard Versus High Dose ED-Initiated Buprenorphine Induction

PHASE3RecruitingINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

December 6, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

December 31, 2028

Conditions
Opioid Use Disorder
Interventions
DRUG

Buprenorphine

All patients will receive 3 pills and will be observed for 2 hours post-study medication administration with repeated COWS at approximately hours 1 and 2. All participants will be given a referral for ongoing MOUD and will be discharged with a prescription for 16 mg daily of buprenorphine daily.

Trial Locations (5)

84132

RECRUITING

University of Utah Hospital, Salt Lake City

94578

RECRUITING

San Leandro Hospital, San Leandro

94602

RECRUITING

Highland Hospital, Oakland

04102

RECRUITING

Maine Medical Center, Portland

08103

RECRUITING

Cooper University Hospital, Camden

All Listed Sponsors
collaborator

National Drug Abuse Treatment Clinical Trials Network

NETWORK

collaborator

The Emmes Company, LLC

INDUSTRY

collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

Alameda Health System

OTHER

lead

Yale University

OTHER